How Much Does Rezdiffra (Resmetirom) Cost in Louisiana in 2026?

Rezdiffra List Price and Louisiana Retail Pricing

The sticker price for Rezdiffra in Louisiana is $3,500 per month, identical to the national manufacturer list price set by Madrigal Pharmaceuticals. That translates to $42,000 per year before insurance adjustments. Because resmetirom is a once-daily oral tablet (not an injectable), there are no infusion-center fees layered on top, but the base drug cost alone places it among the higher-priced liver-targeted therapies on the market.

Why Louisiana Prices Match the National Average

Unlike some specialty drugs that show geographic price variation due to wholesaler markups or state-level dispensing fees, Rezdiffra pricing is uniform. Madrigal distributes through a limited specialty pharmacy network, and Louisiana pharmacies that stock the drug do so at the same wholesale acquisition cost. Patients paying cash at CVS Specialty, Accredo, or local independent specialty pharmacies in Baton Rouge, New Orleans, or Shreveport will see the same $3,500 monthly figure.

How the Price Compares to Other MASH Therapies

Rezdiffra is currently the only FDA-approved pharmacotherapy specifically indicated for metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis stages F2 and F3 1. Before its March 2024 approval, clinicians managed MASH primarily with off-label agents: pioglitazone (roughly $15 to $40 per month generic), vitamin E ($10 to $20 per month OTC), and GLP-1 receptor agonists like semaglutide ($900 to $1,600 per month depending on formulation). Resmetirom occupies a price tier well above pioglitazone and vitamin E but within range of branded GLP-1s when the indication overlaps.

Insurance Coverage for Rezdiffra in Louisiana

Most commercial insurers in Louisiana will cover Rezdiffra, but access almost always requires prior authorization and, in many cases, a step-therapy requirement. Payers want documentation that the patient has biopsy-confirmed or imaging-confirmed MASH with F2 or F3 fibrosis before approving claims.

Commercial Plans: What to Expect

Blue Cross Blue Shield of Louisiana, UnitedHealthcare, Humana, and Aetna plans active in the state have begun adding Rezdiffra to specialty formularies, typically at Tier 4 or Tier 5. Copay obligations at those tiers range from $150 to $500 per month before any manufacturer offset. Some plans require a trial of lifestyle modification or pioglitazone before authorizing resmetirom. Your prescribing hepatologist or gastroenterologist will need to submit clinical notes, fibrosis staging (FibroScan or biopsy results), and sometimes lab evidence of elevated ALT to satisfy the prior authorization criteria.

Louisiana Medicaid: Not Covered

Louisiana Medicaid does not cover Rezdiffra as of May 2026. The state's Medicaid Drug Utilization Review (DUR) Board has not added resmetirom to the preferred drug list. Patients enrolled in Louisiana Medicaid managed care organizations (Aetna Better Health of Louisiana, AmeriHealth Caritas Louisiana, Healthy Blue, or UnitedHealthcare Community Plan) should not expect formulary coverage at this time. This gap is significant: Louisiana expanded Medicaid under the ACA, and approximately 800,000 residents are enrolled. MASH disproportionately affects populations with metabolic syndrome, type 2 diabetes, and obesity, conditions highly prevalent in Louisiana's Medicaid population 2.

Medicare Part D

Medicare Part D plans may cover Rezdiffra, but coverage varies by plan. Patients on Medicare in Louisiana should check their specific Part D formulary. The drug's $3,500 monthly cost means patients can reach the catastrophic coverage threshold relatively quickly. Under the Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D (fully phased in as of 2025), Medicare beneficiaries will pay no more than $2,000 per year total for covered Part D drugs, including Rezdiffra if their plan formulary includes it.

The Madrigal Pharmaceuticals Savings Card

Madrigal offers a copay savings program for commercially insured patients that can reduce out-of-pocket costs to as little as $0 per month, with a maximum annual benefit. The card is accepted at specialty pharmacies dispensing in Louisiana.

Eligibility and Enrollment

To qualify, patients must carry commercial (private) insurance. Government-insured patients (Medicare, Medicaid, Tricare, VA) are excluded by federal anti-kickback statute requirements. Enrollment is handled through the Madrigal patient support hub, and the card is linked to the dispensing pharmacy's claims system. Patients do not receive a physical rebate check. The discount is applied at the point of sale.

Limitations

The savings card has an annual cap (typically $10,000 to $15,000 per year, though Madrigal has adjusted terms periodically). If your commercial plan's cost-sharing exceeds the annual cap, you will be responsible for the remainder. Patients with high-deductible health plans may use the card to offset the deductible-phase cost, but some insurers do not count manufacturer copay assistance toward deductible accumulation. Ask your plan whether copay card payments count as "true out-of-pocket" spending.

Compounded Resmetirom in Louisiana

Louisiana law permits licensed 503A compounding pharmacies to prepare resmetirom formulations. A 503A pharmacy compounds medications pursuant to a valid, patient-specific prescription. The legality of compounding a particular drug depends on whether the active ingredient appears on the FDA's list of bulk drug substances that can be used in compounding and whether the commercial product is in shortage.

Pricing and Access

Compounded resmetirom pricing from 503A pharmacies has been quoted at substantially lower rates than the branded product, in some cases approaching near-zero markup above the cost of the active pharmaceutical ingredient. Actual pricing depends on the compounding pharmacy's sourcing costs and dispensing fees. Patients in Louisiana can access 503A compounding pharmacies in-state or through out-of-state pharmacies licensed to ship into Louisiana.

Quality and Regulatory Considerations

The FDA does not review compounded drugs for safety, efficacy, or manufacturing quality in the same manner as commercially approved products 3. Patients considering compounded resmetirom should discuss this with their prescriber. The MAESTRO-NASH trial (N=966) that supported FDA approval used the branded tablet formulation at 80 mg and 100 mg doses 4. Bioequivalence between a compounded preparation and the branded tablet has not been established in a clinical trial.

Clinical Efficacy: What the Price Buys

Rezdiffra is a thyroid hormone receptor beta (THR-β) selective agonist. It targets the liver specifically, activating pathways that reduce hepatic fat, lower inflammatory markers, and may slow fibrosis progression.

MAESTRO-NASH Results

In the MAESTRO-NASH phase 3 trial (N=966), resmetirom 80 mg achieved MASH resolution without worsening fibrosis in 25.9% of patients at 52 weeks, compared to 9.7% with placebo. The 100 mg dose produced MASH resolution in 29.9% of patients versus 9.7% placebo. Fibrosis improvement by at least one stage (without MASH worsening) occurred in 24.2% of the 80 mg group and 25.9% of the 100 mg group, compared to 14.2% for placebo 5.

Dr. Stephen Harrison, principal investigator of the MAESTRO-NASH trial, stated: "Resmetirom is the first drug to demonstrate statistically significant improvement in both NASH resolution and fibrosis in a registrational trial" 6.

Monitoring and Lab Considerations

Prescribers should check thyroid function (TSH, free T4) before initiating resmetirom and periodically during treatment. The drug's selectivity for THR-β means systemic thyroid effects are minimal, but TSH suppression has been reported. Liver enzymes (ALT, AST) should be monitored, as transient elevations can occur in the first 12 weeks. The FDA label recommends lipid panel monitoring as well, since resmetirom significantly reduces LDL cholesterol (a secondary benefit: mean LDL reduction of 13% to 16% in MAESTRO-NASH) 7.

The Endocrine Society notes that THR-β agonism represents "a mechanistically distinct approach to MASH that addresses hepatic lipotoxicity directly rather than through systemic metabolic pathways" 8.

Telehealth Prescribing in Louisiana

Louisiana permits telehealth prescribing of Rezdiffra. This matters because the state has a limited number of hepatologists. As of 2026, Louisiana has fewer than 80 practicing hepatologists, concentrated in New Orleans, Baton Rouge, and Shreveport. Patients in rural parishes (Concordia, Tensas, East Carroll, and others in the Delta region) may need to travel 2 to 3 hours to see a liver specialist in person.

How Telehealth Prescribing Works

A Louisiana-licensed physician or advanced practice provider can evaluate a patient via synchronous video visit, review imaging and lab results, and prescribe Rezdiffra electronically to a specialty pharmacy. The prescription is then shipped directly to the patient. Louisiana's telehealth parity law (La. R.S. 37:1271.1) requires insurers to cover telehealth services at the same rate as in-person visits, which means the consultation itself should not carry an additional cost barrier.

Specialty Pharmacy Shipping

Most specialty pharmacies that dispense Rezdiffra ship via cold-chain or standard delivery to Louisiana addresses. Delivery is typically within 1 to 3 business days from the pharmacy's distribution hub. Patients do not need to pick up the medication at a brick-and-mortar location unless they prefer to.

Strategies to Lower Your Cost in Louisiana

Paying $3,500 per month without any assistance is a worst-case scenario. Here are the concrete steps Louisiana patients can take to reduce that figure.

Step 1: Verify Insurance Coverage

Call your insurer's pharmacy benefits line (not medical benefits) and ask whether resmetirom (brand name Rezdiffra) is on the formulary. Request the tier, prior authorization requirements, and estimated copay. If denied, ask your prescriber to file a formulary exception with supporting clinical documentation.

Step 2: Apply for the Madrigal Savings Card

If you have commercial insurance, enroll in the Madrigal copay program before filling the first prescription. The card is applied at the specialty pharmacy and can reduce your copay to $0 in many cases.

Step 3: Explore Patient Assistance

Madrigal's patient support program may offer free drug for uninsured or underinsured patients who meet income criteria. Contact the Madrigal patient hub directly. Independent charitable foundations (such as the Patient Access Network Foundation or HealthWell Foundation) may also offer grants for liver disease medications, though Rezdiffra-specific fund availability fluctuates.

Step 4: Ask About Compounded Alternatives

If branded Rezdiffra is financially inaccessible and you are comfortable with a compounded preparation, discuss this option with your prescriber. Ensure the 503A pharmacy is licensed in Louisiana or holds a valid out-of-state shipping license.

Step 5: Use Telehealth to Avoid Added Travel Costs

For patients in rural Louisiana, the cost of repeated 4- to 6-hour round trips to a hepatologist adds up. Using telehealth for follow-up visits (after an initial in-person evaluation and imaging) can save hundreds of dollars per year in travel, lodging, and lost wages.

Who Qualifies for Rezdiffra in Louisiana

The FDA-approved indication is narrow: adults with noncirrhotic MASH and moderate-to-advanced hepatic fibrosis (stages F2-F3) 9. Continued approval depends on confirmatory trials demonstrating clinical outcome benefit. Patients with cirrhosis (F4), decompensated liver disease, or MASH without significant fibrosis (F0-F1) are outside the approved indication.

Diagnosis typically requires either a liver biopsy showing the appropriate NAS (NAFLD Activity Score) and fibrosis stage, or a validated noninvasive combination (e.g., FibroScan with controlled attenuation parameter plus blood-based biomarkers like FIB-4 or ELF score). Louisiana insurers reviewing prior authorization requests generally accept FibroScan results as supporting evidence, though some may still require biopsy confirmation for initial approval.

Louisiana has one of the highest rates of obesity (40.1% of adults, per CDC BRFSS 2023 data) and type 2 diabetes (14.1%) in the United States 10. Both conditions are primary drivers of MASH. The gap between the likely number of Louisiana residents who could benefit from Rezdiffra and the number who can currently access it, given Medicaid non-coverage and the $3,500 monthly price, remains wide.

Patients prescribed Rezdiffra should take the tablet once daily with food. The starting dose is 80 mg for those weighing <100 kg and 100 mg for those weighing ≥100 kg 11.